We want to transform unique innovations and technologies into excellent businesses in the health care sector.
– Why life science? The accelerating need for health care services is met by tremendous efforts in research and development from both the governmental and private sectors. New innovative technologies in life science are being developed with high speed. People with medical and health care needs will increasingly benefit from new and improved treatment options. New treatment options create improved quality of life and reduced mortality for people around the world. Our focus is to identify great entrepreneurs and companies with unique technologies with the potential to bring new important health care products to the life science market. By partnering up with entrepreneurs as well as co-investors, we can exploit the market potential offered by new technologies.
Birk Venture is a private evergreen investment company with a long term and flexible investment approach. We can invest in life science companies both in early stage as well as companies in more developed stage.
We want to build a diversified portfolio of companies in the life science sector. There are some important characteristics and elements that needs to be in place before we invest in a company:
|Medical devices and instruments|
Birk Venture has a rich deal flow. Our deal flow is coming from various sources such as Universities, start-ups or spin-offs from private sector and from co-investors (Private Investment Consortium).
Hans Ivar Robinson has 25 years professional experience in the pharmaceutical and biotech industry including 7 years with capital investments in the life science sector. He has held several leading international positions in AstraZeneca, Pfizer and Pronova Biopharma and several chairman and non-executive positions in smaller biotech companies. His experience covers a broad specter in the pharmaceutical and biotech industry. This includes top management, marketing, sales, business development, licensing, regulatory affairs and broad experience in start-up and development of biotech companies from early pre-clincal to clinical stages. He has extensive experience working with investors and investment banks including capital raising, private placements, mergers and IPOs. He founded Birk Venture in 2010 and holds a M.Sc. from Norwegian School of Economics (NHH).
Co-investor and external partner
Per-Oluf has 27 years experience in the Pharmaceutical and Biotech industry. He has Top management experience from both small and large organization within Pfizer e.g. Country Manager in Norway /Denmark and Italy, Regional Executive Director for Central and Eastern European Region. Last year he has held the position as CEO of Pronova BioPharma AS.
His experience covers all areas of the business from R&D to running a large organization in one of Europe’s biggest market.
Take the long view – It takes hard work and patience to build great companies. There are no short cuts to success. It takes time for markets to emerge and organisations to develop and mature.
Partnership is fundamental – Strong partnership and involvement with people, organisations and stakeholders is essential to succeed with a company.
Enjoy the journey – The journey to success will not be smooth and easy. To handle the ups and downs, it is important to work with people that share the same values, business ideas and trust each other. It very often comes down to chemistry between people and having fun working together.
APIM Therapeutics is a biotechnology company dedicated to the development of novel-cancer agents targeting DNA repair and cell cycle control. The Company is developing a pipeline of peptide compounds that inhibit PCNA-dependent DNA repair in cancer cells. The lead compound, ATX-101, has shown proof-of-concept in multiple preclinical in vitro and in vivo cancer models.
Birk Venture made the first investment in 2011 and has one seat in the board of Directors of the company.
Cortendo AB is a biopharmaceutical company headquartered in Göteborg, Sweden. Its stock is publicly traded on the NOTC-A-list (OTC) in Norway. Cortendo is a pioneer in the field of cortisol inhibition and has completed early clinical trials in patients with Type 2 diabetes. The lead drug candidate NormoCort™, the 2S,4R-enantiomer of ketoconazole, is expected to enter into a Phase 3 study during Q4’2013 for Cushing’s Syndrome. The company’s strategy is to focus its resources to opportunities where the path to commercialization or partnership is clear and relatively near-term. Strategically, Cortendo’s business model is to commercialize relevant opportunities in the United States while partnering its assets ex-US. Backed by a highly experienced leadership team Cortendo has plans to continue to implement its pipeline expansion efforts in osteoarthritis and diabetes, as well as other near term revenue opportunities.
PCI Biotech® (*exited) has developed a unique and patented photochemical drug delivery technology for use in cancer therapy and other diseases.
PCI (PhotoChemical Internalisation) is a technology for light-directed drug delivery by triggered endosomal release and was developed to introduce therapeutic molecules in a biologically active form specifically into diseased cells. The company’s lead candidate drug is the proprietary photosensitiser Amphinex®.
PCI Biotech® has an ongoing clinical phase I/II study at University College Hospital in London. In this study Amphinex® is combined with the cytotoxic agent bleomycin. The study is primarily enrolling patients with Head & Neck cancer, a disease with local control issues that the PCI technology could potentially contribute to solve.
The company has initiated pre-clinical trials for the use of PCI in the treatment of bladder cancer. Bladder cancer has the highest average per-patient life-time cost of all cancers, mainly due to a high recurrence rate. The currently used chemotherapeutic drugs have limited effect on recurrence and progression, and there is a large unmet therapeutic need. Screening studies indicate that the effect of several of these chemotherapeutic drugs may be significantly enhanced by PCI. The pre-clinical trials will be performed at Radboud University Nijmegen, The Netherlands and at The Norwegian University of Science and Technology (NTNU) in Trondheim, Norway.
PCI Biotech® collaborates closely with The Norwegian Radium Hospital in Oslo, Norway and receives substantial funding on several projects from both the Norwegian Research Council and the EU. The company has an extensive international collaboration network with recognised drug delivery expert groups.
Hans Ivar Robinson was together with Anders Tuv guests in “Podcast Radium”, discussing investments and company establishments in the Norwegian biotech sector. https://soundcloud.com/user-972208711/radium-episode-13